Loading...
Loading...
BioReference
Laboratories, Inc.
BRLI announced today that it has entered into a
definitive agreement for the acquisition of Edge BioSystems CLIA laboratory
business and related assets ("Edge BioServ"), primarily a genetic sequencing
service business located in Gaithersburg, MD.
GeneDx, BRLI's wholly-owned clinical diagnostic sequencing laboratory, will
acquire the Edge BioServ genetic sequencing services business, which service
has been offered to a national list of customers. The acquisition will include
sequencing equipment and capabilities that are expected to enhance the ability
of GeneDx to maintain and improve its position as a premier provider of
clinical genetic sequencing services. GeneDx is one of the leading full
service genetic laboratories in the world and the Company believes the
additional capacity and technical expertise that will result from this
acquisition will greatly enhance the opportunity for further growth and
expansion of the GeneDx service offerings. The acquisition will provide GeneDx
with additional equipment on multiple testing platforms operating in a
CLIA-certified environment as well as additional infrastructure for R&D
initiatives. Dean Gaalaas, CEO of EdgeBio, will assume the position of COO at
GeneDx, and will bring with him many of the talented R&D personnel, including
experienced bioinformatics developers.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in